APOE and delirium: Severe adverse ARIA incidents such as delirium, deterioration in memory, and seizures were infrequent, with similar occurrence rates regardless of the individual’s APOE ε4 genotype, at 1.5% in the EMERGE trial and 1.4% in the ENGAGE trial [75,76].